Japan-News

AACR 2018

April 14–18, 2018 | McCormick Place North/South, Chicago, Illinois

イベント

AACR 2018

April 14–18, 2018

McCormick Place North/South, Chicago, Illinois

登録

Empowering the immune system to recognize and eliminate tumors has tremendous potential to change the way cancer is treated and eventually cured. At Fluidigm, we enable comprehensive cellular profiling of the immune system and the tumor microenvironment with proven mass cytometry and microfluidics technologies.

Whether you seek to target new biomarkers and pathways or to optimize the effectiveness of checkpoint inhibitors, CAR T cells or cancer vaccines, Fluidigm can help you gain new insights to reach your next research breakthrough.

Visit Fluidigm at Booth 3420

Exhibit Dates & Hours:
Sunday, April 15: 1:00–5:00 pm
Monday, April 16: 9:00 am–­5:00 pm
Tuesday, April 17: 9:00 am–5:00 pm
Wednesday, April 18: 9:00 am–12:00 pm

Featured Products

Come visit our booth and learn how you can deeply profile tumors and the tumor immune response from every angle.

Hyperion™ Imaging System

Visualize 4 to 37 protein markers in the spatial context of the tissue microenvironment using Imaging Mass Cytometry™.

Hyperion System

Helios™, a CyTOF® system

Deeply profile immune cell subpopulations and identify signatures of checkpoint response using mass cytometry.


Helios
Juno™

Achieve significant cost savings and reduced hands-on time with automated NGS library prep.

Juno

Booth Activities

Interactive tour
Take an interactive tour of the Hyperion Imaging System and learn more about Imaging Mass Cytometry.

Explore! to win
Stop by to visit us and scan the QR code using the Explore! mobile app to be eligible to win prizes.

Meet the experts
Visit with an expert in Imaging Mass Cytometry, mass cytometry, or genomics applications in our booth. Come by during a scheduled hour to ask your questions and network with a technology expert.

Date

Expert, Institution

Application

System

Sunday, April 15th
2:00-3:00 pm
David Rimm, PhD
Yale School of Medicine
Imaging Mass Cytometry Hyperion Imaging System
Monday, April 16th
2:00-3:00 pm
Carsten Krieg, PhD
Medical University of South Carolina
Mass Cytometry Helios, a CyTOF system


Visit presentations and posters featuring Fluidigm technology

Speaker sessions

Title

Presenter

Time
Location

Session

Saturday, April 14 | Imaging Mass Cytometry

Multiplexed measurement of protein targets using Imaging Mass Cytometry™ and Digital Spatial Profiling David L. Rimm, MD, PhD, Yale School of Medicine 11:45 am–12:05 pm
Room S404, McCormick Place South (Level 4)
MW06
Multiplex Imaging of Tumor Tissues: Techniques and Data Analysis

Sunday, April 15 | Mass Cytometry

Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages and can form chimeric mammary glands in vivo Jennifer M. Rosenbluth, MD, Harvard Medical School 4:05–4:20 pm
Room S405, McCormick Place South (Level 4)
MS.TB01.01
Patient-Derived Models of Cancer: Present and Future

Monday, April 16 | Imaging Mass Cytometry

Sequential transcriptomic and phosphorylation landscape of acute myelogenous leukemia (AML) on the single-cell level Victoria E. Wang, MD, PhD, University of California San Francisco 4:35–4:50 pm
Room W196, McCormick Place West (Level 1)
MS.CL01.01
Molecular Predictors of Response, Mediators of Resistance, Mechanisms of Action, Pharmacodynamic Markers, and Novel Disease Subsets

Tuesday, April 17 | Mass Cytometry

Identifying dynamic EMT states and constructing a proteomic EMT landscape of lung cancer using single cell multidimensional analysis Loukia G. Karacosta, PhD, Stanford University 3:05–3:20 pm
Room S106, McCormick Place South (Level 1)
MS.TB04.02
Molecular Mechanisms Driving Metastasis

Wednesday, April 18 | Mass Cytometry and Imaging Mass Cytometry

Single cell mass cytometry reveals clinically and biologically distinct cells in human solid tumors Jonathan M. Irish, PhD, Vanderbilt University 10:15–10:40 am
Room S102, McCormick Place South (level 1)
RADT11
Using Mass Cytometry and MIBI to Monitor Patient Response
Understanding coordination of antitumor immune responses using quantitative single-cell models Matthew Spitzer, PhD, University of California San Francisco School of Medicine 10:45–11:10 am
Room S102, McCormick Place South (Level 1)
RADT11
Using Mass Cytometry and MIBI to Monitor Patient Response
Using mass cytometry to determine cellular mechanisms of combination checkpoint blockade Spencer C. Wei, PhD, University of Texas MD Anderson Cancer Center 11:15–11:40 am
Room S102, McCormick Place South (Level 1)
RADT11
Using Mass Cytometry and MIBI to Monitor Patient Response

Poster sessions

Category

Title

Presenter

Time
Poster Number

Session

Sunday, April 15

Mass Cytometry

Describing prostate cancer heterogeneity through single cell analysis with mass cytometry Laura De Vargas Roditi, PhD,
University Hospital Zurich
1:00–5:00 pm
LB-023/3
LBPO.BSB01.
Late-Breaking Research: Bio-informatics and Systems Biology
Mass Cytometry
Imaging Mass Cytometry
High dimensional single cell analysis predicts response to anti-PD-1 immunotherapy LCarsten Krieg, PhD,
Medical University of South Carolina
1:00–5:00 pm
566/9
PO.CL10.12.
Biomarker Discovery 1
Mass Cytometry MAPK pathway blockade effects on glioma stem cells and immunotherapy in BRAFV600E mutant gliomas Claudia Petritsch, PhD,
University of California San Francisco
1:00–5:00 pm
143/3
PO.TB02.01.
Targeting Cancer Stemness
Mass Cytometry Dynamic immune landscape of the peripheral blood mononuclear cells from recurrent hepatocellular carcinoma patients undergoing radiofrequency ablation treatment Dexi Chen, PhD,
Beijing You An Hospital, Capital Medical University, Beijing Institute of Hepatology
1:00–5:00 pm
610/4
PO.CL06.07.
Immune Response to Therapies 1
Mass Cytometry Uncovering a novel layer of complexity in the architecture of pancreatic cancer Matteo Ligorio, MD,
Massachusetts General Hospital
1:00–5:00 pm
210/10
PO.TB10.01.
Tumor Hetero-geneity 1
Mass Cytometry Tumor endothelial cells as a targetable gateway that modulates access of drugs to cancer cells Yue Wu, PhD,
Roswell Park Cancer Institute
1:00–5:00 pm
190/20
PO.TB06.05.
The Mechanical Micro-environment in Tumori-genesis

Monday, April 16

Imaging Mass Cytometry Functionalizing intratumoral signaling heterogeneity in triple negative breast cancer Amanda L. Rinkenbaugh, PhD,
The University of Texas MD Anderson Cancer Center
1:00–5:00 pm
2181/6
PO.TB10.03.
Tumor Hetero-geneity 3
Mass Cytometry Precise regulation of CAR signaling prevents and reverses CAR T cell exhaustion Evan Weber, PhD,
Stanford University
8:00 am–12:00 pm
LB-111/8
LBPO.IM01.
Late-Breaking Research: Immun-ology 1
Mass Cytometry Dendritic cell based cryoimmunotherapy associates with clinical variables and changes in T-cell receptor expression in a prospective phase I trial of metastatic castration resistant prostate cancer Liv Thomsen, PhD,
Center for Cancer Biomarkers, University of Bergen
8:00 am–12:00 pm
CT066/19
PO.CT02.
Phase I Clinical Trials 2
Mass Cytometry Resistance to radiotherapy and PD-L1 blockade is mediated by TIM-3 upregulation in anti-PD-L1 refractory head and neck cancer Ayman Oweida, PhD,
University of Colorado Denver
1:00–5:00 pm
2766/28
PO.IM02.03.
Immune Mechanisms Invoked by Therapies 1
Mass Cytometry Investigating lung adenocarcinoma tumor heterogeneity with single-cell mass cytometry Maria-Fernanda Senosain-Ortega,
Vanderbilt University
1:00–5:00 pm
2180/5
PO.TB10.03.
Tumor Hetero-geneity 3
Mass Cytometry Individualized drug combination based on single-cell drug perturbations Benedict Anchang, PhD,
Stanford University
1:00–5:00 pm
2275/2
PO.BSB01.05.
New Software for Data Analysis
Mass Cytometry Bone Morphogenetic Protein Receptor 1a in myeloid cells regulates mouse prostate cancer growth Philip Owens, PhD,
University of Colorado
1:00–5:00 pm
2119/4
PO.TB06.03.
The Metastatic Micro-environment
Single-cell Single-cell RNA-seq reveals heterogeneity for stem cell markers, LRG5 and CD271 to predict a subpopulation in Ewing sarcoma cells with lower levels of BRAF Roxane Khoogar,
University of Texas Health Science Center at San Antonio
1:00–5:00 pm
2074/13
PO.TB08.01.
Pediatrics 1: Genomics, Epigenetics, and Biomarkers

Tuesday, April 17

Imaging Mass Cytometry Comparison of Multiplexed Imaging Mass Cytometry™ With Monoplex Immunohistochemistry in FFPE Tissue Navi Mehra, PhD,
Flagship Biosciences
8:00 am–12:00 pm
3037/10
PO.TB07.01.
Cancer Imaging: Immunology and Systems Analysis in Vivo
Mass Cytometry BGB324, a selective small-molecule inhibitor of receptor tyrosine kinase AXL, targets tumor immune suppression and enhances immune checkpoint inhibitor efficacy Gro Gausdal, PhD,
BerGenBio ASA
8:00 am–12:00 pm
3774/24
PO.IM02.07.
Immuno-modulatory Agents and Interventions 1
Mass Cytometry Role of select T helper cell subsets in the development of Epstein-Barr virus-driven lymphoproliferative disease Elshafa Ahmed,
Ohio State University
1:00–5:00 pm
4691/24
PO.IM01.01.
Adaptive Immunity in Tumors
Genomics A cost-effective and rapid assay for profiling of immunobiology and the development of predictive signatures for response to immunotherapies Peilin Chen, PhD,
Fluidigm Corporation
1:00–5:00 pm
4650/15
PO.CL06.05.
Immune Checkpoints 4
Genomics Development of a targeted NGS panel for solid tumor actionable gene targets using multiplex PCR-based enrichment in an integrated fluidic circuit Peilin Chen, PhD,
Fluidigm Corporation
8:00 am–12:00 pm
4651/14
PO.CH01.04.
Drug Discovery Tools
Single-cell Stem cell lineage hierarchy by keratin profiling in normal human prostate epithelial cells and prostate cancer Wenyang Hu, PhD,
University of Illinois at Chicago
8:00 am–12:00 pm
3063/12
PO.TB02.04.
Cancer Stem Cell Character-ization

Wednesday, April 18

Imaging Mass Cytometry Multiplex, single-cell proteomic analysis using Imaging Mass Cytometry™ for circulating tumor cells Sophia Wix,
Bridge @ University of Southern California
8:00 am–12:00 pm
5659/15
PO.CH03.02.
Emerging Proteomic Technologies for Cancer Research
Imaging Mass Cytometry Developing metal-labeled antibody panels for multiplex proteomic characterization of rare circulating tumor cells by Imaging Mass Cytometry™ Milind Pore, PhD,
University of Southern California
David and Dana Dornsife
College of Letters, Arts, and Sciences
8:00 am–12:00 pm
5656/12
PO.CH03.02.
Emerging Proteomic Technologies for Cancer Research
Mass Cytometry Single-cell mass cytometry of classical Hodgkin lymphoma defines an exhausted and immunosuppressive microenvironment Fathima Cader, PhD,
Dana-Farber Cancer Institute
8:00 am–12:00 pm
5675/11
PO.IM01.05.
Emerging Tools and Models in Immuno-Oncology Research
Mass Cytometry The impact of combination oral azacitidine (CC-486) + pembrolizumab (PEMBRO) on the immune infiltrate in metastatic melanoma (MM) Emily Keung, MD,
The University of Texas MD Anderson Cancer Center
8:00 am–12:00 pm
5711/17
PO.IM02.04.
Immune Monitoring/ Clinical Correlates
Mass Cytometry SAUCIE: Sparse autoencoder for unsupervised clustering, imputation, and embedding Matthew Amodio,
Yale University
8:00 am–12:00 pm
5306/14
PO.BSB01.06.
New Algorithms
Mass Cytometry Mass cytometry identifies the expansion, persistence, and immune checkpoints of adoptively transferred memory-like NK cells in patients with leukemia Todd Fehniger, MD, PhD
Washington University School of Medicine
8:00 am–12:00 pm
5704/10
PO.IM02.04.
Immune Monitoring/ Clinical Correlates
Genomics DNA methylation index of lifetime estrogen exposure in breast cancer Annelie Johansson,
Imperial College London
8:00 am–12:00 pm
5316/5
PO.MCB05.05.
DNA Methylation
Single-cell Transcriptome profiling of single prostate cancer cells following androgen deprivation Ashlee Clark, PhD,
Monash University
8:00 am–12:00 pm
5234/8
PO.EN02.01.
Clinical Endo-crinology
Single-cell Single-cell RNAseq of human prostate cancer-associated fibroblasts reveals distinct subpopulations that may promote inflammatory cell recruitment to the tumor microenvironment Renee Vickman, PhD,
NorthShore University HealthSystem
8:00 am–12:00 pm
5075/14
PO.TB06.07.
Carcinoma- Associated Fibroblasts in Tumor Progression

For Research Use Only. Not for use in diagnostic procedures.